Reliable Proliferation And Differentiation Of Desired T Cell Subpopulations With CellGenix® Recombinant Human Interleukin-2 (IL-2)

By Gilli Galore Haskel, Efrat Merhavi-Shoham, Sivan Ofir, Naama Dror, Mika Shapiro, Roni Bareli, Andres Castillo, Shanya Jiang, Gaurav Kaushik, Rohit Saklecha, Remmer Janssen, Jalil Hakimi, Adva Maimon, Kat Kozyrytska, Maya Fuerstenau-Sharp

Here, we compare the effectiveness of CellGenix® Preclinical Recombinant Human IL-2 with Proleukin®, a standard IL-2 cytokine, in expanding T cells for immune therapies like CAR-T. The use of IL-2 is critical in promoting T cell proliferation, essential for both research and clinical-grade cell therapies. Transitioning from research-grade to GMP-grade cytokines can increase manufacturing costs and timelines, creating a need for materials like CellGenix® IL-2, which provides consistency across development and clinical phases.

The study involved stimulating peripheral blood mononuclear cells (PBMCs) from two donors with either CellGenix® or Proleukin® IL-2 across two different media. Key performance metrics—such as total cell growth, CD4+/CD8+ ratios, and specific T cell subpopulations—were monitored over 10 days. Results showed that CellGenix® IL-2 performed comparably to Proleukin®, achieving similar fold expansions and viable cell counts. Moreover, subpopulation ratios, including memory and effector T cells, were consistent across treatments and media types.

These findings demonstrate that CellGenix® IL-2 offers a reliable, animal-free, and cost-effective alternative to Proleukin® without compromising quality or clinical utility. The seamless transition from preclinical to GMP-grade cytokines minimizes process disruptions and reduces the need for extensive revalidation. This makes CellGenix® IL-2 an attractive option for manufacturers developing immune-based therapies, ensuring high-quality results from research through to clinical production.